In vitro and integrated in vivo strategies to reduce animal use in genotoxicity testing.


Journal

Mutagenesis
ISSN: 1464-3804
Titre abrégé: Mutagenesis
Pays: England
ID NLM: 8707812

Informations de publication

Date de publication:
29 11 2021
Historique:
received: 10 06 2021
accepted: 17 09 2021
pubmed: 24 9 2021
medline: 8 3 2022
entrez: 23 9 2021
Statut: ppublish

Résumé

Scientific, financial, and ethical drivers have led to unprecedented interest in implementing human-relevant, mechanistic in vitro and in silico testing approaches. Further, as non-animal approaches are being developed and validated, researchers are interested in strategies that can immediately reduce the use of animals in toxicology testing. Here, we aim to outline a testing strategy for assessing genotoxicity beginning with standard in vitro methods, such as the bacterial reverse mutation test and the in vitro micronucleus test, followed by a second tier of in vitro assays including those using advanced 3D tissue models. Where regulatory agencies require in vivo testing, one demonstrated strategy is to combine genotoxicity studies traditionally conducted separately into a single test or to integrate genotoxicity studies into other toxicity studies. Standard setting organisations and regulatory agencies have encouraged such strategies, and examples of their use can be found in the scientific literature. Employing approaches outlined here will reduce animal use as well as study time and costs.

Identifiants

pubmed: 34555171
pii: 6374588
doi: 10.1093/mutage/geab035
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

389-400

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Katherine Groff (K)

PETA Science Consortium International e.V., Stuttgart, Germany.

Stephen J Evans (SJ)

Institute of Life Science, Swansea University, UK.

Shareen H Doak (SH)

Institute of Life Science, Swansea University, UK.

Stefan Pfuhler (S)

Procter & Gamble Co., Mason, OH, USA.

Raffaella Corvi (R)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Samantha Saunders (S)

PETA Science Consortium International e.V., Stuttgart, Germany.

Gilly Stoddart (G)

PETA Science Consortium International e.V., Stuttgart, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH